publication date: Jul. 31, 2014


html aml.html

Volasertib and LDAC Doubled Response in Older Acute Myeloid Leukemia Patients

A phase II study of older patients with untreated acute myeloid leukemia showed that treatment with volasertib and low-dose cytarabine more than doubled the objective response rate compared to cytarabine chemotherapy alone.

The study data were published in the American Society of Hematology journal Blood. Volasertib, sponsored by Boehringer Ingelheim, has not been approved by the FDA, and its safety and efficacy have not been established.

The rate of objective response, either complete remission or complete remission with incomplete blood count recovery, was 31 percent for patients receiving volasertib and LDAC, compared to 13.3 percent for LDAC alone (p=0.052).

The secondary endpoints of the study were overall survival, event-free survival, relapse-free survival and safety.

Patients treated with volasertib combined with LDAC had a median overall survival of 8 months compared to 5.2 months in patients treated with LDAC (p=0.047).

Median event-free survival was prolonged in patients receiving volasertib and LDAC versus LDAC: 5.6 months versus 2.3 months, respectively (p=0.021). Relapse-free survival for volasertib and LDAC versus LDAC was 18.5 months versus 10 months.

The open-label study enrolled 87 adult patients, with a median age of 75 years, with AML considered unsuitable for intensive induction therapy.

Patients were randomized in a 1:1 ratio to receive the combination of LDAC plus volasertib 350 mg intravenously over one hour on days 1 and 15 versus LDAC 20 mg twice daily subcutaneously on days 1-10 alone. Cycles were scheduled every four weeks until progression, relapse, intolerance, or requested discontinuation.

Volasertib is an investigational … Continue reading CCL July – Volasertib and LDAC Doubled Response in Older Acute Myeloid Leukemia Patients

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.